Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 2:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 53 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: FASENRA(benralizumab) Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

NCT02155660
View directory record Official record
Conditions
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions
Benralizumab Arm A, Benralizumab Arm B, Benralizumab Arm C, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
2,255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
151
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Montgomery, Alabama + 127 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 1, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA

NCT02258542
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 75 Years
Enrollment
2,133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
100
States / cities
Andalusia, Alabama • Birmingham, Alabama • Scottsboro, Alabama + 80 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 1, 2026, 2:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Sequential Dose-Escalation Study in Subjects With Mild Asthma

NCT00512486
View directory record Official record
Conditions
Asthma
Interventions
MEDI-563
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
3
States / cities
Denver, Colorado • North Darthmouth, Massachusetts • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 27, 2008 · Synced Oct 1, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma

NCT04305405
View directory record Official record
Conditions
Severe Uncontrolled Asthma
Interventions
Benralizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 14 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Los Angeles, California • Orlando, Florida • Lincoln, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Oct 1, 2026, 2:04 PM EDT
Not listed Phase 2Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome

NCT02130882
View directory record Official record
Conditions
Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders, Hypereosinophilia
Interventions
benralizumab, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 1, 2026, 2:04 PM EDT
Terminated No phase listed Observational

Benralizumab Pregnancy Exposure Study

NCT03794999
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab-exposure, Exposure to other asthma medications
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 1, 2026, 2:04 PM EDT
Recruiting Phase 4 Interventional

Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

NCT06385236
View directory record Official record
Conditions
Moderate to Severe Asthma
Interventions
Dupilumab, Benralizumab
Biological
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • La Jolla, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 1, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home

NCT02918071
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
14
States / cities
Northridge, California • Riverside, California • Westminster, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 1, 2026, 2:04 PM EDT
Completed Phase 4 Interventional

Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody

NCT03183024
View directory record Official record
Conditions
Chronic Idiopathic Urticaria
Interventions
benralizumab, placebo
Biological
Lead sponsor
Jonathan A. Bernstein, MD
Other
Eligibility
19 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 1, 2026, 2:04 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis

NCT05006573
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
Benralizumab, Placebo to Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Newport Beach, California • Northridge, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 1, 2026, 2:04 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

NCT05966584
View directory record Official record
Conditions
Breast Cancer
Interventions
Benralizumab, fulvestrant or AIs) and PI3K inhibition (alpelisib)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 1, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation

NCT02869438
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
16
States / cities
Scottsboro, Alabama • Gilbert, Arizona • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 1, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

NCT04552288
View directory record Official record
Conditions
Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Hematologic Malignancy
Interventions
Benralizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 1, 2026, 2:04 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis

NCT04605094
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Benralizumab, Placebo / Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Newport Beach, California • Bridgeport, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 1, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma

NCT02814643
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Benralizumab Placebo, Seasonal influenza virus vaccine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 21 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Birmingham, Alabama • Mesa, Arizona • Huntington Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 1, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma

NCT02322775
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
17
States / cities
Los Angeles, California • Rolling Hills Estates, California • Clearwater, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Oct 1, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01227278
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo, Benralizumab 100 mg
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
40 Years to 85 Years
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
9
States / cities
Los Angeles, California • Marietta, Georgia • Normal, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 1, 2026, 2:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma

NCT00659659
View directory record Official record
Conditions
Asthma
Interventions
MEDI-563, Placebo Comp., Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
6
States / cities
Denver, Colorado • Pittsburgh, Pennsylvania • Galveston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Oct 1, 2026, 2:04 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)

NCT04612725
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Benralizumab, Placebo and Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Scottsdale, Arizona • Los Angeles, California • Mission Viejo, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 1, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis

NCT03401229
View directory record Official record
Conditions
Nasal Polyposis
Interventions
Benralizumab 30 mg SC + Mometasone Furoate, Matching placebo SC + Mometasone Furoate
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
48
States / cities
Birmingham, Alabama • Fresno, California • Huntington Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 1, 2026, 2:04 PM EDT
Recruiting Phase 3 Interventional

A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

NCT06512883
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)
Interventions
Benralizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Aurora, Colorado • Cincinnati, Ohio • Highland Hills, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 1, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).

NCT00768079
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Benralizumab
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
9
States / cities
Tampa, Florida • Springfield, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 1, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma

NCT01928771
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 75 Years
Enrollment
2,681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
110
States / cities
Foley, Alabama • Huntsville, Alabama • Mobile, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 1, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma

NCT03557307
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
23
States / cities
Flagstaff, Arizona • Los Angeles, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Oct 1, 2026, 2:04 PM EDT